Drug intelligence / Profile preview

(2e)-N-allyl-4-{[3-(4-bromophenyl)-5-fluoro-1-methyl-1h-indazol-6-yl]oxy}-N-methyl-2-buten-1-amine

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a synthetic small molecule with the formula C22H23BrFN3O and a molecular weight of approximately 444.34 g/mol. It is referenced in chemical databases such as PubChem (CID 445990), DrugBank (DB02139), and ChEMBL (CHEMBL65730). The structure features an indazole core substituted with bromine and fluorine atoms, as well as allyl and methyl groups on the amine moiety. There is no evidence that this compound has been approved for clinical use or entered clinical trials; it appears to be an experimental or research chemical. Its mechanism of action is not established in public sources; however, it has been studied as a ligand in structural biology contexts—specifically associated with squalene-hopene cyclase protein structures—suggesting possible use as an enzyme inhibitor or probe in biochemical research[7][8][10]. No therapeutic indications are known.

Other names: (2E)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1H-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine[(2E)-4-{[3-(4-bromophenyl)-5-fluoro 1-methyl 1H-indazol 6-yl]oxy}but‑2‑en‑1‑yl](methyl)(prop‑2‑en‑1‑yl)amine

Targets

SHC1 (Squalene-hopene cyclase)

Beyond the preview

Go deeper on (2e)-N-allyl-4-{[3-(4-bromophenyl)-5-fluoro-1-methyl-1h-indazol-6-yl]oxy}-N-methyl-2-buten-1-amine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2e)-N-allyl-4-{[3-(4-bromophenyl)-5-fluoro-1-methyl-1h-indazol-6-yl]oxy}-N-methyl-2-buten-1-amine.

Explore the full profile